SARS-CoV-2 seroprevalence and implications for population immunity : Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022
© 2023 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd..
BACKGROUND: We sought to estimate SARS-CoV-2 antibody seroprevalence within representative samples of the Kenyan population during the third year of the COVID-19 pandemic and the second year of COVID-19 vaccine use.
METHODS: We conducted cross-sectional serosurveys among randomly selected, age-stratified samples of Health and Demographic Surveillance System (HDSS) residents in Kilifi and Nairobi. Anti-spike (anti-S) immunoglobulin G (IgG) serostatus was measured using a validated in-house ELISA and antibody concentrations estimated with reference to the WHO International Standard for anti-SARS-CoV-2 immunoglobulin.
RESULTS: HDSS residents were sampled in February-June 2022 (Kilifi HDSS N = 852; Nairobi Urban HDSS N = 851) and in August-December 2022 (N = 850 for both sites). Population-weighted coverage for ≥1 doses of COVID-19 vaccine were 11.1% (9.1-13.2%) among Kilifi HDSS residents by November 2022 and 34.2% (30.7-37.6%) among Nairobi Urban HDSS residents by December 2022. Population-weighted anti-S IgG seroprevalence among Kilifi HDSS residents increased from 69.1% (65.8-72.3%) by May 2022 to 77.4% (74.4-80.2%) by November 2022. Within the Nairobi Urban HDSS, seroprevalence by June 2022 was 88.5% (86.1-90.6%), comparable with seroprevalence by December 2022 (92.2%; 90.2-93.9%). For both surveys, seroprevalence was significantly lower among Kilifi HDSS residents than among Nairobi Urban HDSS residents, as were antibody concentrations (p < 0.001).
CONCLUSION: More than 70% of Kilifi residents and 90% of Nairobi residents were seropositive for anti-S IgG by the end of 2022. There is a potential immunity gap in rural Kenya; implementation of interventions to improve COVID-19 vaccine uptake among sub-groups at increased risk of severe COVID-19 in rural settings is recommended.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Influenza and other respiratory viruses - 17(2023), 9 vom: 01. Sept., Seite e13173 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 03.10.2023 published: Print Citation Status Publisher |
|---|
| doi: |
10.1111/irv.13173 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362484007 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362484007 | ||
| 003 | DE-627 | ||
| 005 | 20231226091335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/irv.13173 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362484007 | ||
| 035 | |a (NLM)37752065 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kagucia, E Wangeci |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 seroprevalence and implications for population immunity |b Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: We sought to estimate SARS-CoV-2 antibody seroprevalence within representative samples of the Kenyan population during the third year of the COVID-19 pandemic and the second year of COVID-19 vaccine use | ||
| 520 | |a METHODS: We conducted cross-sectional serosurveys among randomly selected, age-stratified samples of Health and Demographic Surveillance System (HDSS) residents in Kilifi and Nairobi. Anti-spike (anti-S) immunoglobulin G (IgG) serostatus was measured using a validated in-house ELISA and antibody concentrations estimated with reference to the WHO International Standard for anti-SARS-CoV-2 immunoglobulin | ||
| 520 | |a RESULTS: HDSS residents were sampled in February-June 2022 (Kilifi HDSS N = 852; Nairobi Urban HDSS N = 851) and in August-December 2022 (N = 850 for both sites). Population-weighted coverage for ≥1 doses of COVID-19 vaccine were 11.1% (9.1-13.2%) among Kilifi HDSS residents by November 2022 and 34.2% (30.7-37.6%) among Nairobi Urban HDSS residents by December 2022. Population-weighted anti-S IgG seroprevalence among Kilifi HDSS residents increased from 69.1% (65.8-72.3%) by May 2022 to 77.4% (74.4-80.2%) by November 2022. Within the Nairobi Urban HDSS, seroprevalence by June 2022 was 88.5% (86.1-90.6%), comparable with seroprevalence by December 2022 (92.2%; 90.2-93.9%). For both surveys, seroprevalence was significantly lower among Kilifi HDSS residents than among Nairobi Urban HDSS residents, as were antibody concentrations (p < 0.001) | ||
| 520 | |a CONCLUSION: More than 70% of Kilifi residents and 90% of Nairobi residents were seropositive for anti-S IgG by the end of 2022. There is a potential immunity gap in rural Kenya; implementation of interventions to improve COVID-19 vaccine uptake among sub-groups at increased risk of severe COVID-19 in rural settings is recommended | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Health and Demographic Surveillance System | |
| 650 | 4 | |a IgG antibody | |
| 650 | 4 | |a Kenya | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a seroprevalence | |
| 700 | 1 | |a Ziraba, Abdhala K |e verfasserin |4 aut | |
| 700 | 1 | |a Nyagwange, James |e verfasserin |4 aut | |
| 700 | 1 | |a Kutima, Bernadette |e verfasserin |4 aut | |
| 700 | 1 | |a Kimani, Makobu |e verfasserin |4 aut | |
| 700 | 1 | |a Akech, Donald |e verfasserin |4 aut | |
| 700 | 1 | |a Ng'oda, Maurine |e verfasserin |4 aut | |
| 700 | 1 | |a Sigilai, Antipa |e verfasserin |4 aut | |
| 700 | 1 | |a Mugo, Daisy |e verfasserin |4 aut | |
| 700 | 1 | |a Karanja, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Gitonga, John |e verfasserin |4 aut | |
| 700 | 1 | |a Karani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Toroitich, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Karia, Boniface |e verfasserin |4 aut | |
| 700 | 1 | |a Otiende, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Njeri, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Aman, Rashid |e verfasserin |4 aut | |
| 700 | 1 | |a Amoth, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Mwangangi, Mercy |e verfasserin |4 aut | |
| 700 | 1 | |a Kasera, Kadondi |e verfasserin |4 aut | |
| 700 | 1 | |a Ng'ang'a, Wangari |e verfasserin |4 aut | |
| 700 | 1 | |a Voller, Shirine |e verfasserin |4 aut | |
| 700 | 1 | |a Ochola-Oyier, Lynette I |e verfasserin |4 aut | |
| 700 | 1 | |a Bottomley, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Nyaguara, Amek |e verfasserin |4 aut | |
| 700 | 1 | |a Munywoki, Patrick K |e verfasserin |4 aut | |
| 700 | 1 | |a Bigogo, Godfrey |e verfasserin |4 aut | |
| 700 | 1 | |a Maitha, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Uyoga, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Gallagher, Katherine E |e verfasserin |4 aut | |
| 700 | 1 | |a Etyang, Anthony O |e verfasserin |4 aut | |
| 700 | 1 | |a Barasa, Edwine |e verfasserin |4 aut | |
| 700 | 1 | |a Mwangangi, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Bejon, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Adetifa, Ifedayo M O |e verfasserin |4 aut | |
| 700 | 1 | |a Warimwe, George M |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, J Anthony G |e verfasserin |4 aut | |
| 700 | 1 | |a Agweyu, Ambrose |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Influenza and other respiratory viruses |d 2007 |g 17(2023), 9 vom: 01. Sept., Seite e13173 |w (DE-627)NLM176605215 |x 1750-2659 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:9 |g day:01 |g month:09 |g pages:e13173 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/irv.13173 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 9 |b 01 |c 09 |h e13173 | ||